Journal
CANCER LETTERS
Volume 486, Issue -, Pages 8-17Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.04.024
Keywords
HCC; NUPR1; ZZW-115; Necroptosis; Apoptosis
Categories
Funding
- La Ligue Contre le Cancer
- INCa
- Canceropole PACA
- INSERM
- Fondation de France
- China Scholarship Council
- Programme XU GUANGQI
- National Natural Science Foundation of China [81502920]
- Fundamental Research Funds for the Central Universities [106112017CDJQJ468823]
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [18394]
Ask authors/readers for more resources
HCC is a highly lethal malignancy with Sorafenib as the only molecularly targeted drug. The multifunctional stress-associated protein, NUPR1, plays an essential role in controlling cell growth, migration, invasion and Sorafenib resistance in HCC. We report here that NUPR1 expression is absent in healthy liver and it is progressively upregulated in HCC premalignant lesions such as hepatitis and cirrhosis with a maximum expression in HCC samples, highlighting that NUPR1 is a potential drug target for HCC. We therefore assessed in this work, ZZW-115, a strong inhibitor of NUPR1, as a promising candidate for the treatment of HCC. We validated its extraordinary antitumor effect on HCC by using two HCC cell lines, HepG2-and Hep3B, both in cell based experiments and xenografted mice. We further revealed that ZZW-115 treatment induced cell death by apoptosis and necroptosis mechanisms, with a concomitant mitochondrial metabolism failure that triggers lower ATP production. Furthermore, the ATP depletion cannot be rescued by the apoptosis inhibitor Z-VAD-FMK and/or the necrosis inhibitor Necrostatin-1, indicating that ZZW-115 induces cell death through the mitochondrial failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available